Related references
Note: Only part of the references are listed.
Article
Pharmacology & Pharmacy
Rana Abdelnabi et al.
Summary: The infectivity of the omicron variant in hamsters was found to be lower than that of the ancestral D614G strain, with a significant decrease in viral RNA load in the lungs and no detectable infectious virus in this organ. Histopathological examination of the lungs from omicron-infected hamsters revealed no signs of peri-bronchial inflammation or bronchopneumonia.
ANTIVIRAL RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Katharina Roltgen et al.
Summary: During the SARS-CoV-2 pandemic, different vaccines have been used globally. This study compares the antibodies generated by mRNA vaccines, infection, and other types of vaccines. It shows that mRNA vaccines result in a better antibody breadth against viral variants compared to infection. Infection leads to variant-specific antibodies, while mRNA vaccination imprints responses towards the original virus strain. mRNA vaccines also stimulate robust germinal centers in lymph nodes, enhancing the immune response.
Article
Biochemistry & Molecular Biology
Katherine J. Siddle et al.
Summary: An outbreak of COVID-19 cases in Provincetown, Massachusetts in July 2021, primarily affecting vaccinated individuals, was caused by the Delta variant. Genomic and epidemiological data indicated multiple transmissions of Delta among fully vaccinated individuals. Despite the large-scale outbreak, it had limited onward impact due to high vaccination rates and a robust public health response.
Review
Virology
Dandan Tian et al.
Summary: During the COVID-19 pandemic, various variants of SARS-CoV-2 have emerged, showing increased infectivity and immune escape, posing new challenges to epidemic prevention and control.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Letter
Medicine, General & Internal
Constanze Kuhlmann et al.
Letter
Medicine, General & Internal
Annika Fendler et al.
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.
Article
Multidisciplinary Sciences
Raquel Viana et al.
Summary: The SARS-CoV-2 epidemic in southern Africa has experienced three distinct waves, driven by different variants. The recently identified Omicron variant has rapidly spread in South Africa and to numerous countries, raising global concern.
Article
Multidisciplinary Sciences
Peter J. Halfmann et al.
Summary: The recent study by the SAVE/NIAID network shows that the B.1.1.529 Omicron variant causes milder lung disease in rodents, which is consistent with preliminary human clinical data.
Article
Biochemistry & Molecular Biology
Paul R. Wratil et al.
Summary: This study reports on the dynamics of neutralizing antibodies in individuals convalescing from coronavirus disease 2019 or who are vaccine-naive and subsequently vaccinated. The findings suggest that infection-plus-vaccination-induced hybrid immunity or triple immunization can induce high-quality antibodies with superior neutralization capacity against variants of concern, including omicron.
Letter
Medicine, General & Internal
Shirley Collie et al.
Summary: Preliminary data from a test-negative study design in South Africa showed that two doses of the BNT162b2 vaccine had an efficacy of 50 to 70% against hospitalization caused by the omicron variant in Gauteng province.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Editorial Material
Medicine, General & Internal
Roby P. Bhattacharyya et al.
Summary: While Omicron's spread in South Africa has resulted in fewer hospitalizations and deaths per documented case compared to previous waves, caution should be exercised when making inferences about Omicron's intrinsic severity using population-level observations.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cell Biology
M. Cyrus Maher et al.
Summary: This study predicts future variants of SARS-CoV-2 by analyzing various factors affecting its evolution, including ACE2-mediated transmissibility and host immunity. The researchers successfully identified mutations that will emerge in different phases of the pandemic and assessed their impact on therapeutic antibodies. This modeling approach has important implications for predicting emerging variants of SARS-CoV-2 and can be applied to other rapidly evolving pathogens.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Letter
Immunology
Pragya D. Yadav et al.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Public, Environmental & Occupational Health
Mark G. Thompson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2022)
Article
Microbiology
Bert Vanmechelen et al.
Summary: We report the first confirmed case of an infection with the Omicron variant in Europe, identified from a Belgian patient who recently traveled to Egypt.
MICROBIOLOGY RESOURCE ANNOUNCEMENTS
(2022)
Article
Multidisciplinary Sciences
Juliet R. C. Pulliam et al.
Summary: This study provides two methods for monitoring reinfection trends in routine surveillance data. The results suggest immune evasion by the Omicron variant in previously infected individuals in South Africa, and there has been an increase in the risk of having a third infection since mid-November 2021.
Article
Cell Biology
Yang Liu et al.
Summary: This study reports that the P681R mutation in the Delta spike plays a crucial role in the replacement of the Alpha variant by the Delta variant during the COVID-19 pandemic. The Delta variant outcompetes the Alpha variant in human lung cells and airway tissues. The P681R mutation enhances the cleavage of the spike protein, leading to increased replication of the Delta variant.
Article
Microbiology
Ketaki Ganti et al.
Summary: This study investigates the factors affecting the transmission of SARS-CoV-2, including exposure timing, temperature, and humidity. The research shows that even a one-hour exposure can lead to robust transmission. The timing of exposure relative to infection is a critical determinant of transmission success, with little or no spread occurring before 16 hours or after 48 hours post-infection. The infectious viral titers in the nasal tract are strongly correlated with the likelihood of transmission.
Article
Medicine, General & Internal
Takuya Tada et al.
Summary: This study found that the Omicron variant has significantly reduced sensitivity to neutralization by vaccines and vaccine-elicited antibodies. However, a booster immunization can enhance the neutralizing effect against Omicron. In addition, individuals with a history of prior SARS-CoV-2 infection showed increased neutralizing activity against Omicron. Different monoclonal antibodies showed varying effectiveness against the Omicron variant.
Article
Medicine, General & Internal
Ji Ma et al.
Summary: This study demonstrates that the YF-S0 vaccine can induce strong humoral and cellular immunity against yellow fever virus (YFV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice and hamsters, providing full protection against YFV infection and SARS-CoV-2 strain B1.1.7 (Alpha variant) infection. Importantly, strong pre-existing immunity against the YF17D vector does not interfere with the efficacy of YF-S0 vaccination.
Article
Medicine, Research & Experimental
Jonathan W. Yewdell et al.
Summary: Original antigenic sin (OAS) is a phenomenon in antibody responses to influenza A virus infection or vaccination, which depends on multiple variables. It is not a sin, but rather a part of evolutionary selection that can help improve influenza virus vaccines.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
(2021)
Article
Multidisciplinary Sciences
Lorena Sanchez-Felipe et al.
Summary: The candidate vaccine YF-S0, utilizing the YF17D vaccine as a vector to express noncleavable prefusion form of the SARS-CoV-2 spike antigen, showed excellent safety, immunogenicity, and efficacy in animal models. It induced high levels of neutralizing antibodies, provided protective immunity against SARS-CoV-2, and prevented infection in hamsters and macaques. A single dose was able to confer protection from lung disease in most vaccinated hamsters within 10 days, highlighting the potential of YF-S0 as a potent SARS-CoV-2 vaccine candidate.
Article
Multidisciplinary Sciences
Jarek Juraszek et al.
Summary: Researchers have successfully created a stable variant of the SARS-CoV-2 S protein through structure-based design, with increased expression and correct folding predominantly in a closed prefusion conformation. This contributes to supporting vaccine development efforts.
NATURE COMMUNICATIONS
(2021)
Article
Microbiology
Allison J. Greaney et al.
Summary: The evolution of SARS-CoV-2 may impact the recognition of the virus by human antibody-mediated immunity, with mutations affecting antibody binding varying significantly among individuals and within the same individual over time. Despite this variability, mutations that greatly reduce antibody binding usually occur at specific sites in the RBD, with E484 being the most crucial. These findings can inform surveillance efforts for SARS-CoV-2 evolution in the future.
CELL HOST & MICROBE
(2021)
Editorial Material
Medicine, General & Internal
Ester C. Sabino et al.
Article
Multidisciplinary Sciences
Dami A. Collier et al.
Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.
Article
Multidisciplinary Sciences
Pengfei Wang et al.
Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.
Article
Multidisciplinary Sciences
Alexander Muik et al.
Summary: A new SARS-CoV-2 lineage B.1.1.7 has emerged in the UK, which is more transmissible and faster spreading than other strains. However, a study found that the BNT162b2 vaccine offers largely preserved protection against the B.1.1.7 lineage, despite some reduced neutralizing titers.
Review
Immunology
Nikolaos C. Kyriakidis et al.
Summary: The new SARS-CoV-2 virus is rapidly spreading worldwide, causing the COVID-19 pandemic with more than 1.866 million deaths. Over 64 vaccine candidates are being developed globally, aiming to induce antibodies to prevent viral entry. Thirteen vaccine candidates are currently in Phase 3 clinical trials, showing promising progress towards approval for large-scale immunizations.
News Item
Medicine, General & Internal
Ingrid Torjesen
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Review
Oncology
Eleonora Cella et al.
Summary: The SARS-CoV-2 virus, originating in Wuhan, China, rapidly spread globally, with advanced whole-genome sequencing technologies providing valuable insights into the virus's evolution and epidemiology during the pandemic. Monitoring global SARS-CoV-2 lineages is useful for specific diagnosis, better care, and timely treatment, while characterizing circulating lineages helps understand virus genetic diversity and dispersion dynamics.
Review
Immunology
Dandan Tian et al.
Summary: The Delta variant of the SARS-CoV-2 virus, first reported in India in October 2020 and classified as a variant of concern by the WHO in May 2021, is highly transmissible and associated with increased hospitalization, ICU admission, and mortality rates. It has become the dominant strain in many countries globally.
FRONTIERS IN IMMUNOLOGY
(2021)
News Item
Medicine, General & Internal
Rita Rubin
Summary: Efficiency of COVID-19 vaccines against SARS-CoV-2 variants is still being studied.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
S. A. Madhi et al.
Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Joan E. M. van der Lubbe et al.
Summary: This study investigated the immunogenicity, protective efficacy, and potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S in a Syrian hamster challenge model with the G614 spike SARS-CoV-2 variant. Results showed that higher vaccine doses elicited substantial neutralizing antibodies titers and provided complete protection against lung infection and pneumonia in over 80% of Syrian hamsters inoculated with SARS-CoV-2.
Article
Public, Environmental & Occupational Health
Mark S. Graham et al.
Summary: The study showed that the B.1.1.7 variant did not result in changes in COVID-19 symptoms or duration of illness, and there was no significant increase in reinfection rate compared to previous variants.
LANCET PUBLIC HEALTH
(2021)
Article
Biochemistry & Molecular Biology
Darren P. Martin et al.
Summary: The emergence of the 501Y lineages of SARS-CoV-2 in 2020 coincided with a global shift in selective forces acting on various genes, leading to repeated convergent mutations at 35 genome sites known as the 501Y meta-signature. This meta-signature includes multiple mutation combinations that promote the persistence of diverse SARS-CoV-2 lineages in the face of increasing host immune recognition.
Review
Biochemistry & Molecular Biology
Edward C. Holmes et al.
Summary: This article critically reviews the current scientific evidence to help clarify the origin of SARS-CoV-2. Recent debate has centered around two competing ideas: a laboratory escape scenario and zoonotic emergence.
Article
Biochemistry & Molecular Biology
Fatima Amanat et al.
Summary: After receiving the SARS-CoV-2 spike mRNA vaccine, individuals showed robust polyclonal antibody responses, with a majority of vaccine-induced antibodies lacking neutralizing activity. However, vaccine-induced RBD binding antibodies may offer substantial protection against viral variants carrying single E484K RBD mutations.
Article
Multidisciplinary Sciences
Jingyou Yu et al.
Summary: The Ad26.COV2.S vaccine provides robust protection against the B.1.351 variant in rhesus macaques, despite generating lower neutralizing antibodies against B.1.351 compared to the WA1/2020 strain.
Article
Multidisciplinary Sciences
Jianying Liu et al.
Summary: Serum samples from individuals vaccinated with the BNT162b2 vaccine can neutralize various SARS-CoV-2 variants, indicating mass immunization as a central strategy to end the global COVID-19 pandemic.
Review
Microbiology
William T. Harvey et al.
Summary: The evolution of SARS-CoV-2 has been characterized by the emergence of mutations and variants that impact virus characteristics. Manufacturers are preparing for possible updates to vaccines in response to changes in the virus population, and it is crucial to monitor genetic and antigenic changes alongside experiments to understand the impacts of mutations.
NATURE REVIEWS MICROBIOLOGY
(2021)
Article
Multidisciplinary Sciences
Stacey A. Lapp et al.
Summary: Murine exposure to HKU1 spike protein inhibited the development of neutralizing antibodies to SARS-CoV-2, while the presence of HKU1 spike IgG antibodies in children with acute COVID-19 or MIS-C did not diminish neutralizing antibody responses to SARS-CoV-2.
Article
Cell Biology
Lisa H. Tostanoski et al.
Summary: This study explored how mutations in spike proteins of different SARS-CoV-2 variants affect natural and vaccine-induced immunity, finding that primary infection with the WA1/2020 strain provided strong protection, while antibodies induced by the Ad26.COV2.S vaccine showed reduced neutralizing activity against the B.1.351 strain but still offered effective protection.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Medicine, General & Internal
Rana Abdelnabi et al.
Summary: The global COVID-19 pandemic has resulted in over 108 million infections and 2.4 million deaths within a year, with new variants of concern emerging. Research on prototypic VoC from B.1.1.7 and B.1.351 variants in hamsters revealed efficient infection of the lower respiratory tract and highlighted the need for assessing vaccine and therapeutic efficacy against these variants.
Letter
Immunology
Takahisa Fujino et al.
Summary: Different variants of SARS-CoV-2 with higher transmission potential have been emerging globally, including one found in travelers from Brazil to Japan in January 2021, which carries an additional set of mutations.
EMERGING INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Sin Fun Sia et al.
Article
Multidisciplinary Sciences
Hongjing Gu et al.
Article
Multidisciplinary Sciences
Ching-Lin Hsieh et al.
Article
Multidisciplinary Sciences
Suzanne J. F. Kaptein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)
Article
Multidisciplinary Sciences
Robbert Boudewijns et al.
NATURE COMMUNICATIONS
(2020)
Article
Medicine, General & Internal
Florian Krammer et al.
NATURE REVIEWS DISEASE PRIMERS
(2018)
Article
Biochemical Research Methods
Michael A. Whitt
JOURNAL OF VIROLOGICAL METHODS
(2010)
Article
Multidisciplinary Sciences
DJ Smith et al.
